Encouraging when very limited choices are available for PD treatment.
fResults. Exenatide was well tolerated, although weight loss was common and l-dopa dose failures occurred in a single patient. Single-blinded rating of the exenatide group suggested clinically relevant improvements in PD across motor and cognitive measures compared with the control group. Exenatide-treated patients had a mean improvement at 12 months on the MDS-UPDRS of 2.7 points, compared with mean decline of 2.2 points in control patients (P = 0.037).
Conclusion. These results demonstrate a potential cost-efficient approach through which preliminary clinical data of possible biological effects are obtainable, prior to undertaking the major investment required for double-blind trials of a potential disease-modifying drug in PD.
Trial registration. Clinicaltrials.gov NCT01174810.
See JCI for more details on this PD trial. 8% of PD & Dementia? Not sure of market potential.
Perhaps chance correlation, very small study- but interesting news on dementia front.
......At both 12 and 14 months, a significant advantage in the Mattis dementia rating scale–2 (Mattis DRS-2) was seen in patients treated with exenatide, with a mean improvement of 2.8 points at 14 months compared with deterioration by a mean of 3.5 points in control patients....... See the JCI story if you google Exantide Alzheimer's.
Google "Exanetide Parkinson's", Yahoo would not let me post link. Bydureon is different form of Exanetide....I think the long acting? I wonder why this news to not post to Reuter's or other company news sites. Only the research sites.